Ambrosia Biosciences Inc.

Ambrosia Biosciences Inc.

Private
Boulder, ColoradoHealthcare & Life Scienceshttps://ambrosiabiosciences.com

Last Round

Series B

Mar 31, 2026

Total Funding Raised

$141M

Company Overview

Ambrosia Biosciences Inc. is a biotechnology company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

oral GLP-1small molecule drugsobesity drugsdrug discovery platformAI drug discoverystructure-based drug discoveryweight loss drugsG-protein coupled receptorsGPCRsGLP-1 receptor agonistmetabolic disordersdrug licensingClass B GPCRscryo-EMpreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ambrosia Biosciences Inc. Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ambrosia Biosciences Inc. Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMar 31, 2026
Series ADec 10, 2024
Series AAug 20, 2024

Key People

Founding team and executive leadership

Nick Traggis

Founder And CEO, Member Board Of Directors

Founding Team

Ambrosia Biosciences Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Presenting at the American Diabetes Association's 86th Scientific Session.

  • Mar 31, 2026

    Sara Clarke joins the Board of Directors.

Ambrosia Biosciences Inc. Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ambrosia Biosciences Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ambrosia Biosciences Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBoulder, Colorado
Employee Range34
Year Founded2024
Last FundingMar 31, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.